China Betaferon Adherence, Coping and Nurse Support Study

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Non-adherence reduces treatment benefit and can bias the assessment of treatment efficacy thereby involving safety risks for the patient and influencing health cost-effectiveness. This observational study will concentrate upon the role of MS nurses in influencing adherence. This study will examine the influence of initial and subsequent periodic nurse interviews which aim to improve adherence to Betaferon® treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Interferon beta-1b; Interferon-beta; Interferons

Criteria

Inclusion Criteria:

• Relapsing-remitting multiple scelrosis (RRMS) and secondary progressive multiple sclerosis (SPMS) patients

• Having Betaferon treatment, including patients who are

• First time using; or

• Re-staring; or

• Switching from other diseases modifying drugs (DMDs)

Exclusion Criteria:

• Known or newly identified contraindication for administration of Betaferon according to Summary of Product Characteristic (SmPC).